Pharmaceutical News

RSS

Biologists identify protein targets for next-generation of anti-HIV drugs

People infected with the Human Immunodeficiency Virus (HIV) can stave off the symptoms of AIDS thanks to drug cocktails that mainly target three enzymes produced by the virus, but resistant strains pop up periodically that threaten to thwart these drug combos.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

Patients' race or ethnicity linked with differences in prescription of HIV drug

A lot of evidence shows that a patients' race or ethnicity is associated with differences in how health care providers communicate with them, the health care they receive, and their health outcomes.

28 Jan 2014

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer.

28 Jan 2014

New versions of old antibiotic offers strategy for overcoming drug resistance

Research led by St. Jude Children's Research Hospital scientists has produced new versions of an old antibiotic that are active against difficult-to-treat tuberculosis; offers new strategy for overcoming drug resistance

28 Jan 2014

Study shows taking vitamin D2 supplements may result in higher muscle damage in athletes

Power athletes and others looking for an edge to improve their performance should avoid taking vitamin D2.

28 Jan 2014

Study finds new class of semisynthetic anti-tuberculosis agents that overcome native drug efflux

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a method to synthesize modified forms of an established antibiotic called spectinomycin.

27 Jan 2014

Researchers find novel drug combination approach to speed fight against cancer

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way.

27 Jan 2014

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

...

27 Jan 2014

Cannabis during pregnancy results in defective development of fetal nerve cells

An increasing number of children suffer from the consequences of maternal drug exposure during pregnancy, and Cannabis is one of the most frequently used substances.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

27 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

26 Jan 2014

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

Cantrell Drug Company today announced amendment of its U.S. Food and Drug Administration (FDA) registration to include the new 503B "compounding outsourcing facility" designation established under the recently passed Drug Quality and Security Act so that it can continue to serve patients nationwide with sterile medications that meet the most exacting quality standards.

25 Jan 2014

New drugs for treatment of prostate cancer may not target root cause of the disease

NEW drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published today (Friday, 24 January 2014) in Cell Death & Differentiation.

25 Jan 2014

Aspirin intake correlates with halted growth of lethal intracranial tumor

Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

24 Jan 2014

FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.

24 Jan 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Study examines existing evidence related to health benefits of vitamin D

A new study concludes that evidence is lacking for substantial health benefits of vitamin D – and that results of several multimillion-dollar trials currently underway are unlikely to alter this view.

24 Jan 2014

Pharmaceutical News

Biologists identify protein targets for next-generation of anti-HIV drugs

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Patients' race or ethnicity linked with differences in prescription of HIV drug

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

New versions of old antibiotic offers strategy for overcoming drug resistance

Study shows taking vitamin D2 supplements may result in higher muscle damage in athletes

Study finds new class of semisynthetic anti-tuberculosis agents that overcome native drug efflux

Researchers find novel drug combination approach to speed fight against cancer

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

Cannabis during pregnancy results in defective development of fetal nerve cells

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

New drugs for treatment of prostate cancer may not target root cause of the disease

Aspirin intake correlates with halted growth of lethal intracranial tumor

FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

NICE approves MabThera for treating severe forms of GPA and MPA

Study examines existing evidence related to health benefits of vitamin D

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News